To: Principal Investigators (PI) of Animal Use

Memorandum for Record: Nomenclature of Buprenorphine SR and Buprenorphine ER

Purpose: To establish understanding in buprenorphine nomenclature during the transition of former supplier to current supplier.

1. Animal use protocols frequently use buprenorphine for analgesia. Recently the primary supplier (ZooPharm) was bought out by Wedgewood Pharmacy leading to a change in the name of the product.
   a. ZooPharm product is called Buprenorphine Sustained Release (BupSR).
   b. Wedgewood Pharmacy product is called Buprenorphine Extended Release (BupER).
   c. Both products are of the same concentration and perform the same.

2. The JHU Animal Care and Use (ACUC) Office has determined that we will view references to these two substances as equal. This is to ensure a proper transition from one product to another. The following apply:
   a. Older animal use protocols may refer to BupSR. If the PI starts using BupER, there is no protocol violation.
   b. A PI may continue to use BupSR that is on hand until expiration, no matter which of the two substances are described in the animal use protocol/amendment.
   c. New amendments and animal use protocols shall now refer to BupER.
   d. No protocols will require an amendment to change nomenclature during this transition.

3. This Memorandum shall remain in place until all supplies of BupSR are exhausted and all protocols referencing BupSR have expired, no later than three years from the date on this Memorandum.

4. Keep this document with your controlled substances log.

5. Point of contact for this memorandum is the undersigned.

Brendan Canning
IACUC Chairperson, ACUC, JHU